Mykofenolan Mofetylu Accord (Mycophenolate Mofetil)

Mycophenolate Mofetil, the active ingredient in Mykofenolan Mofetylu Accord, is an immunosuppressant presented as an intravenous formulation for infusion use. It is employed to reduce the risk of acute rejection in patients who have received organ transplants, acting on the immune system to limit lymphocyte proliferation.

GNH USA supplies Mykofenolan Mofetylu Accord as a licensed, GDP‑compliant international pharmaceutical product to hospitals, transplant centres and pharmacies worldwide. The company adheres to stringent quality standards and regulatory requirements across EU markets.

Mycophenolate Mofetil is used as an immunosuppressive agent to prevent organ rejection following transplantation.

Prevention of acute organ transplant rejection: reduces the incidence of graft rejection by inhibiting lymphocyte proliferation.

Mycophenolate Mofetil may be associated with a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools that may lead to dehydration. - Headache: transient cranial discomfort. - Infections: increased susceptibility to bacterial, viral or fungal infections. - Anemia: reduction in red blood cell count. - Leukopenia: decreased white blood cell count.

Serious or Rare Side Effects: - Opportunistic infections: such as Pneumocystis jirovecii pneumonia. - Malignancy: increased risk of lymphoproliferative disorders. - Severe hepatic injury: marked elevation of liver enzymes or hepatitis. - Progressive multifocal leukoencephalopathy (PML): rare demyelinating disease. - Bone marrow failure: aplastic anemia or pancytopenia.

When using Mykofenolan Mofetylu Accord, clinicians should observe several safety measures. - Monitor blood counts: perform regular CBC to detect leukopenia or anemia. - Assess renal function: adjust therapy if creatinine clearance declines. - Avoid live vaccines: immunosuppression may cause uncontrolled infection. - Screen for infections: treat active infections before initiating therapy. - Pregnancy and breastfeeding: use only if benefits outweigh risks; discuss with specialist. - Store at below 25°C: keep in original container, protect from moisture and light.

Mycophenolate Mofetil interacts with several agents that may alter its efficacy or safety.

Major Interactions (Avoid): - Azathiine: additive bone marrow suppression. - Cyclosporine: increased mycophenolate exposure leading to toxicity. - Tacrolimus: heightened risk of nephrotoxicity and infections.

Moderate Interactions (Monitor Closely): - Antacids containing aluminum or magnesium: may reduce absorption. - Cholestyramine: can bind drug and lower plasma levels. - Live attenuated vaccines: may cause disease due to immunosuppression.